ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
3.14B
Market cap3.14B
Price-Earnings ratio
8.87
Price-Earnings ratio8.87
Dividend yield
—
Dividend yield—
Average volume
4.10M
Average volume4.10M
High today
$18.73
High today$18.73
Low today
$17.94
Low today$17.94
Open price
$18.54
Open price$18.54
Volume
485.04K
Volume485.04K
52 Week high
$30.96
52 Week high$30.96
52 Week low
$15.86
52 Week low$15.86

Stock Snapshot

ACADIA Pharmaceuticals(ACAD) stock is priced at $18.17, giving the company a market capitalization of 3.14B. It carries a P/E multiple of 8.87.

As of 2026-11-17, ACADIA Pharmaceuticals(ACAD) stock has fluctuated between $17.94 and $18.73. The current price stands at $18.17, placing the stock +1.3% above today's low and -3.0% off the high.

The ACADIA Pharmaceuticals(ACAD)'s current trading volume is 485.04K, compared to an average daily volume of 4.1M.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $30.96 and a 52-week low of $15.86.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $30.96 and a 52-week low of $15.86.

ACAD News

Investing.com 4h
ACADIA at UBS Global Biopharma Conference 2026: sales momentum builds - Investing.com

...

ACADIA at UBS Global Biopharma Conference 2026: sales momentum builds - Investing.com
TipRanks 1d
Acadia Pharmaceuticals enters distribution agreement with Kyorin Pharmaceutical

Acadia Pharmaceuticals (ACAD) announced that it has entered into an exclusive distribution agreement with Kyorin Pharmaceutical, for the commercialization of Da...

TipRanks 4d
Acadia Pharmaceuticals price target lowered to $24 from $28 at Morgan Stanley

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $24 from $28 and keeps an Equal Weight rating on the shar...

Analyst ratings

75%

of 20 ratings
Buy
75%
Hold
20%
Sell
5%

More ACAD News

Seeking Alpha 7d
Acadia gains after oral arguments in Nuplazid patent dispute

On the Move Acadia gains after oral arguments in Nuplazid patent dispute Nov 10, 2026, 2:18 PM ET Acadia Pharmaceuticals Inc. (ACAD) Stock By : Dulan Lokuwithan...

Acadia gains after oral arguments in Nuplazid patent dispute

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.